tiprankstipranks
Denali Therapeutics (DNLI)
NASDAQ:DNLI
US Market
DNLI
Denali Therapeutics
RESEARCH TOOLSreports
Want to see DNLI full AI Analyst Report?

Denali Therapeutics (DNLI) Stock News & Sentiment

882 Followers
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
Premium
Ratings
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
8d ago
DNLI
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
Premium
Ratings
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
11d ago
DNLI
Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
Premium
Ratings
Denali Therapeutics: Differentiated PGRN Strategy and AVLAYAH Strength Support Buy Rating and Higher $39 Target Despite Biology Risks
1M ago
DNLI
Denali Regains DNL593 Rights After Takeda Collaboration Ends
Premium
Company Announcements
Denali Regains DNL593 Rights After Takeda Collaboration Ends
2M ago
8K
DNLI
Denali Therapeutics Secures $200 Million Royalty Funding
Premium
Company Announcements
Denali Therapeutics Secures $200 Million Royalty Funding
2M ago
8K
DNLI
Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
Premium
Ratings
Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
2M ago
DNLI
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
Premium
Ratings
Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation
2M ago
DNLI
More DNLI News >

DNLI News on the Web

Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
MarketBeat
Bullish
Why Denali Therapeutics Stock Is Sliding Now
TipRanks News
Neutral
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
TipRanks News
Neutral
Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Definitive Healthcare Corp (DH) and Denali Therapeutics (DNLI)
TipRanks News
Bullish
Denali Therapeutics: AVLAYAH Momentum and Pipeline Progress Support Buy Rating, $39 Price Target Maintained
TipRanks News
Bullish
Denali Therapeutics (DNLI) Gets a Buy from Bank of America Securities
TipRanks News
Bullish
Denali Therapeutics: Buy Rating on AVLAYAH Launch Momentum and Undervalued Blood–Brain Barrier TV Platform
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
DNLI
Sector Average
Media Buzz
This Week5 articles
Weekly Average2.25 articles
News Sentiment
This Week99%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DNLI’s Media Buzz Sentiment?
5 articles about DNLI were published this week. In an average week, 2.25 articles are published.
    What is DNLI’s weekly average amount of articles?
    In an average week, 2.25 articles about DNLI are published.
      What is DNLI’s News Sentiment?
      99% of articles about DNLI were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        DOCSDoximity
        AVAHAveanna Healthcare Holdings
        AQSTAquestive Therapeutics
        GOSSGossamer Bio
        HTFLHeartFlow, Inc.
        Showing the stocks with the most bullish news sentiment over the past week